Bristol-Myers Squibb Company
BMY
$47.85
$1.302.79%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -46.66% | 3,311.11% | -94.05% | -27.92% | 114.10% |
| Total Depreciation and Amortization | -2.96% | -45.21% | -29.75% | 1.39% | 3.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 351.97% | -71.34% | 2,929.27% | -90.26% | -96.51% |
| Change in Net Operating Assets | 100.80% | -246.63% | -25.25% | 171.99% | -1,297.47% |
| Cash from Operations | 100.46% | -55.98% | -20.60% | 140.37% | -17.93% |
| Capital Expenditure | -38.85% | 31.22% | -16.67% | -23.66% | 7.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -265.38% | -65.96% | 86.49% | 74.65% | 93.15% |
| Divestitures | 11.11% | -27.03% | 30.59% | -5.56% | 12.03% |
| Other Investing Activities | 75.99% | -288.46% | -152.53% | 330.43% | -90.38% |
| Cash from Investing | 5.21% | -154.59% | 10.50% | 83.40% | 93.28% |
| Total Debt Issued | -84.24% | 190.86% | -526.32% | -70.86% | -97.96% |
| Total Debt Repaid | -- | -- | 100.00% | 12.12% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -0.32% | -3.28% | -0.16% | 0.08% | -0.41% |
| Other Financing Activities | 110.68% | -442.11% | -218.75% | 366.67% | 93.81% |
| Cash from Financing | -84.89% | 39.52% | 57.37% | 4.25% | -127.47% |
| Foreign Exchange rate Adjustments | 93.94% | 144.90% | -290.91% | 450.00% | 51.11% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 228.79% | -78.48% | 53.66% | 152.57% | -39.04% |